Stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer: Does beam-on time matter?

• Published in: Japanese journal of clinical oncology Vol. 50; no. 10; pp. 1182 - 1187
• Main Authors: Hurmuz, Pervin, Cengiz, Mustafa, Ozyigit, Gokhan, Akkas, Ebru Atasever, Yuce, Deniz, Yilmaz, Melek Tugce, Yildiz, Demet, Zorlu, Faruk, Akyol, Fadil
• Format: Journal Article
• Language: English
• Published: 01-10-2020
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyaa093

Abstract
Purpose
Stereotactic body radiotherapy (SBRT) is an effective treatment option for patients with early-stage non-small cell lung cancer (NSCLC). In this study, we evaluated the treatment results using two different SBRT techniques and the effect of beam-on time (BOT) on treatment outcomes.
Methods
Between July 2007 and January 2018, 142 patients underwent SBRT for primary NSCLC. We have delivered SBRT using either respiratory tracking system (RTS) or internal-target-volume (ITV)-based motion management techniques. The effect of age, tumor size, pretreatment tumor SUVmax value, presence of tissue diagnosis, histopathological subtype, operability status, tumor location, motion management technique, BED10 value, BOT on overall survival (OS), loco-regional control (LRC), event-free survival (EFS) and primary tumor control (PTC) were evaluated.
Results
Median age of the patients was 70 years (range, 39–91 years). Most of the patients were inoperable (90%) at the time of SBRT. Median BED10 value was 112.5 Gy. With a median follow-up of 25 months, PTC was achieved in 91.5% of the patients. Two-year estimated OS, LRC, PTC and EFS rates were 68, 63, 63 and 53%, respectively. For the entire group, OS was associated with BOT (P = 0.027), and EFS was associated with BOT (P = 0.027) and tumor size (P = 0.015). For RTS group, OS was associated with age (P = 0.016), EFS with BOT (P = 0.05) and tumor size (P = 0.024), LRC with BOT (P = 0.008) and PTC with BOT (P = 0.028). The treatment was well tolerated in general.
Conclusion
SBRT is an effective and safe treatment with high OS, LRC, EFS and PTC rates in patients with primary NSCLC. Protracted BOT might deteriorate SBRT outcomes.